Biomm S.A.

São Paulo Stock Exchange BIOM3.SA

Biomm S.A. Revenue for the year ending December 31, 2023: USD 24.31 M

Biomm S.A. Revenue is USD 24.31 M for the year ending December 31, 2023, a 22.96% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Biomm S.A. Revenue for the year ending December 31, 2022 was USD 19.77 M, a 3.09% change year over year.
Biomm S.A. Revenue for the year ending December 31, 2021 was USD 19.18 M, a 70.18% change year over year.
Biomm S.A. Revenue for the year ending December 31, 2020 was USD 11.27 M, a 407.07% change year over year.
Biomm S.A. Revenue for the year ending December 31, 2019 was USD 2.22 M, a 451.82% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

São Paulo Stock Exchange: BIOM3.SA

Biomm S.A.

CEO	Mr. Heraldo Carvalho Marchezini
IPO Date	Jan. 11, 2000
Location	Brazil
Headquarters	Rua dos Pinheiros, 610
Employees	130
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Biomm S.A. operates as a biotechnology company in Brazil. It offers AFREZZA, a human insulin inhalation powder; CONFORT CARE, a moisturizing foot cream; GLARGILIN, a glargine insulin; and HERZUMA, a trastuzumab. Biomm S.A. was founded in 2001 and is based in São Paulo, Brazil.

Key trends

Past 5 years